Retatrutide evidence brief — weight, metabolic, bone & lean mass

Spot-checked numbers

Verified against Europe PMC abstracts

Phase 2 obesity trial (Jastreboff 2023, NEJM): 48-week LS mean weight change −8.7% / −17.1% / −22.8% / −24.2% (1 / 4 / 8 / 12 mg) vs −2.1% placebo verified against abstract
DXA body-composition substudy (Coskun 2025, Lancet Diabetes Endocrinol.): fat-mass change at 36 weeks −15.2% / −26.1% / −23.2% (4 / 8 / 12 mg) vs −2.6% dulaglutide and −4.5% placebo verified against abstract
Same DXA abstract: lean-mass proportion of weight loss “similar to other obesity treatments” (qualitative; no BMD figures) verified against abstract

Not verified / thin evidence: No published retatrutide DXA abstract in this run reported bone mineral density (BMD) outcomes. Semaglutide / tirzepatide body-composition comparisons in the bone/lean answer are context from other trials / narrative, not head-to-head DXA vs retatrutide — treat as unverified comparative framing unless checked in those primary papers.

Weight loss, metabolic outcomes & safety

Question: clinical-trial evidence for retatrutide (LY3437943) on weight loss, metabolic outcomes, and safety.

Headline phase 2 result at 48 weeks: −24.2% mean body weight at 12 mg verified against abstract

Clinical Trial Evidence for Retatrutide (LY3437943)

Weight Loss Efficacy

Retatrutide demonstrates substantial dose-dependent weight reduction in clinical trials. In the pivotal 48-week phase 2 obesity trial (n=338), least-squares mean percentage changes in body weight were:

1 mg: -8.7%
4 mg: -17.1%
8 mg: -22.8%
12 mg: -24.2%
Placebo: -2.1%

At 48 weeks, clinically significant weight loss thresholds were achieved by high proportions of participants: ≥5% weight loss in 92-100% (vs. 27% placebo), ≥10% in 75-93% (vs. 9% placebo), and ≥15% in 60-83% (vs. 2% placebo) across the 4-12 mg dose range [1].

A Bayesian network meta-analysis of 19 RCTs (n=29,506) confirmed retatrutide's superior efficacy, with mean weight loss of -11.0 kg, equivalent to dual agonists but surpassing GLP-1 receptor agonists (-9.0 kg). Retatrutide demonstrated the highest odds ratio for achieving ≥15% weight loss (OR 54.6) compared to dual agonists (OR 16.4) and GLP-1RAs (OR 9.0) [6].

Metabolic Outcomes

Liver Fat and MASLD

In participants with metabolic dysfunction-associated steatotic liver disease and ≥10% liver fat (n=98), retatrutide produced dramatic reductions in liver fat at 24 weeks:

1 mg: -42.9%
4 mg: -57.0%
8 mg: -81.4%
12 mg: -82.4%
Placebo: +0.3%

Normal liver fat (<5%) was achieved by 27-86% of retatrutide-treated participants versus 0% with placebo. These improvements correlated significantly with reductions in body weight, abdominal fat, and markers of insulin sensitivity and lipid metabolism [2].

Glycemic Control

In the phase 3 TRANSCEND-T2D-1 trial (n=537) of adults with type 2 diabetes inadequately controlled by diet and exercise, retatrutide as monotherapy achieved substantial HbA1c reductions at 40 weeks:

4 mg: -1.69% (difference vs. placebo: -0.88%)
9 mg: -1.86% (difference: -1.04%)
12 mg: -1.94% (difference: -1.12%)
Placebo: -0.81%

All comparisons were highly significant (p<0.0001). Body weight reductions ranged from -11.5% to -15.3% versus -2.6% with placebo [5].

Cardiometabolic Parameters

The phase 2 obesity trial demonstrated significant improvements in:

Waist circumference: -10.51 cm
Fasting plasma glucose: -23.51 mg/dL
Systolic blood pressure: -9.88 mmHg
Diastolic blood pressure: -3.88 mmHg [4]

Multi-omic profiling in preclinical models revealed coordinated metabolic reprogramming in adipose tissue, including suppressed lipogenesis, enhanced fatty acid oxidation, improved mitochondrial function, and reduced inflammatory/fibrotic pathways [11].

Safety and Side Effects

Gastrointestinal Effects

The most common adverse events were gastrointestinal in nature, occurring in a dose-dependent manner but generally mild to moderate in severity. These included nausea, diarrhea, and vomiting. Starting with a lower initial dose (2 mg vs. 4 mg) partially mitigated these effects [1].

Discontinuation Rates

Study drug discontinuation due to adverse events was relatively low: 2-5% with retatrutide versus 0% with placebo in the TRANSCEND-T2D-1 trial [5]. The network meta-analysis indicated retatrutide had the highest adverse event risk among incretin-based therapies, though events were predominantly gastrointestinal and transient [6].

Cardiovascular Effects

Dose-dependent increases in heart rate were observed, peaking at 24 weeks and declining thereafter [1]. Preclinical cardiac studies in isolated mouse and human atrial preparations demonstrated positive chronotropic and inotropic effects mediated through cAMP-dependent pathways via glucagon receptor activation [8,10].

Hypoglycemia

No severe hypoglycemia was reported in the type 2 diabetes monotherapy trial [5].

Mortality

Two deaths occurred during the phase 3 trial, both in the 4 mg retatrutide group and deemed unrelated to study drug [5].

Mechanism of Action

Retatrutide's unique triple agonism targets GLP-1, GIP, and glucagon receptors, enabling coordinated effects on appetite suppression, insulin secretion, energy expenditure, and lipid metabolism [3,7]. This multi-receptor activation produces synergistic metabolic benefits beyond single or dual agonist approaches, representing a paradigm shift in obesity pharmacotherapy [12].

Clinical Context

Meta-regression analysis revealed that type 2 diabetes reduced weight loss efficacy by approximately 4-5 kg for GLP-1RAs and dual agonists, with enhanced outcomes observed in female-predominant or high-BMI cohorts [6]. The ongoing TRANSCEND-CKD mechanistic study is evaluating retatrutide's effects on kidney function in patients with chronic kidney disease [9].

References

[1] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. 2023. https://doi.org/10.1056/nejmoa2301972" rel="noopener" target="_blank">https://doi.org/10.1056/nejmoa2301972

[2] Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. 2024. https://doi.org/10.1038/s41591-024-03018-2" rel="noopener" target="_blank">https://doi.org/10.1038/s41591-024-03018-2

[3] Li W, et al. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. 2024. https://doi.org/10.1038/s41421-024-00700-0" rel="noopener" target="_blank">https://doi.org/10.1038/s41421-024-00700-0

[4] Abdrabou Abouelmagd A, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. 2025. https://doi.org/10.1080/08998280.2025.2456441" rel="noopener" target="_blank">https://doi.org/10.1080/08998280.2025.2456441

[5] Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. 2026. https://doi.org/10.1016/s0140-6736(26" rel="noopener" target="_blank">https://doi.org/10.1016/s0140-6736(26)00967-0

[6] Sinha B, Ghosal S. Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. 2025. https://doi.org/10.1002/oby.24360" rel="noopener" target="_blank">https://doi.org/10.1002/oby.24360

[7] Katsi V, et al. Retatrutide-A Game Changer in Obesity Pharmacotherapy. 2025. https://doi.org/10.3390/biom15060796" rel="noopener" target="_blank">https://doi.org/10.3390/biom15060796

[8] Neumann J, et al. Contractile effects of retatrutide in isolated mouse atrial preparations. 2025. https://doi.org/10.1007/s00210-025-04335-0" rel="noopener" target="_blank">https://doi.org/10.1007/s00210-025-04335-0

[9] Heerspink HJL, et al. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. 2026. https://doi.org/10.1093/ndt/gfaf230" rel="noopener" target="_blank">https://doi.org/10.1093/ndt/gfaf230

[10] Neumann J, et al. Inotropic effects of retatrutide in isolated human atrial preparations. 2026. https://doi.org/10.1007/s00210-025-04421-3" rel="noopener" target="_blank">https://doi.org/10.1007/s00210-025-04421-3

[11] Li Q, et al. Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair. 2026. https://doi.org/10.1186/s13098-026-02116-0" rel="noopener" target="_blank">https://doi.org/10.1186/s13098-026-02116-0

[12] Ganamurali N, Sabarathinam S. The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities. 2026. https://doi.org/10.1002/cpdd.70001" rel="noopener" target="_blank">https://doi.org/10.1002/cpdd.70001

Weight & metabolic sources

[1] Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. (2023) — https://doi.org/10.1056/nejmoa2301972

[2] Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. (2024) — https://doi.org/10.1038/s41591-024-03018-2

[3] Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. (2024) — https://doi.org/10.1038/s41421-024-00700-0

[4] Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. (2025) — https://doi.org/10.1080/08998280.2025.2456441

[5] Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. (2026) — https://doi.org/10.1016/s0140-6736(26)00967-0

[6] Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. (2025) — https://doi.org/10.1002/oby.24360

[7] Retatrutide-A Game Changer in Obesity Pharmacotherapy. (2025) — https://doi.org/10.3390/biom15060796

[8] Contractile effects of retatrutide in isolated mouse atrial preparations. (2025) — https://doi.org/10.1007/s00210-025-04335-0

[9] Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. (2026) — https://doi.org/10.1093/ndt/gfaf230

[10] Inotropic effects of retatrutide in isolated human atrial preparations. (2026) — https://doi.org/10.1007/s00210-025-04421-3

[11] Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair. (2026) — https://doi.org/10.1186/s13098-026-02116-0

[12] The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities. (2026) — https://doi.org/10.1002/cpdd.70001

Bone mineral density & lean mass (DXA)

Question: effects on BMD and lean / muscle mass vs semaglutide and tirzepatide.

Plain finding: A dedicated DXA substudy reports substantial fat-mass loss and a lean-mass loss proportion similar to other obesity drugs. No BMD numbers appear in that abstract — bone density evidence for retatrutide looks thin / unpublished in this literature pull.

Evidence on Retatrutide's Effects on Body Composition

Body Composition Effects from DXA Substudies

Fat Mass Reduction

A dedicated DXA substudy in people with type 2 diabetes (n=189) demonstrated that retatrutide produced dose-dependent reductions in total body fat mass at 36 weeks [4]:

Retatrutide 4 mg: -15.2% (SE 3.2%)
Retatrutide 8 mg: -26.1% (SE 2.5%)
Retatrutide 12 mg: -23.2% (SE 3.0%)
Dulaglutide 1.5 mg: -2.6% (SE 1.6%)
Placebo: -4.5% (SE 1.2%)

Compared to placebo, the reductions were statistically significant for doses ≥4 mg (p=0.0013 for 4 mg; p<0.0001 for 8 mg and 12 mg) [4].

Lean Body Mass and Muscle Preservation

The same substudy found that the proportion of lean mass loss to total weight loss with retatrutide was similar to other obesity treatments [4]. The authors specifically noted: "The proportion of lean mass loss to weight loss was similar to other obesity treatments. These findings could provide reassurance that a greater proportion of lean mass is not lost with retatrutide despite the overall increased weight loss" [4].

This is a critical finding, as it suggests that despite producing substantially greater total weight loss (up to 24.2% at 48 weeks with 12 mg dose [1]), retatrutide does not disproportionately compromise lean body mass compared to existing therapies.

Bone Mineral Density

No specific data on bone mineral density (BMD) effects were reported in the available DXA substudies [4]. The published body composition analysis focused on fat mass and lean mass compartments but did not include BMD measurements or assessments.

Comparison with Semaglutide and Tirzepatide

Direct Comparisons Available

The retatrutide DXA substudy included dulaglutide 1.5 mg as an active comparator but did not include semaglutide or tirzepatide [4]. Direct head-to-head DXA comparisons with semaglutide or tirzepatide are not available in the published literature.

Indirect Comparisons - Weight Loss Magnitude

While direct body composition comparisons are lacking, the overall weight loss achieved with retatrutide substantially exceeds that reported with semaglutide and tirzepatide:

Retatrutide 12 mg at 48 weeks: -24.2% mean weight loss, with 83% achieving ≥15% weight reduction [1]
Retatrutide 8 mg at 48 weeks: -22.8% mean weight loss, with 75% achieving ≥15% weight reduction [1]

For context, published trials of semaglutide 2.4 mg typically show ~15% weight loss, and tirzepatide 15 mg shows ~20-22% weight loss at similar timepoints, though direct comparisons from the same trial populations are not available.

Fat Mass Reduction Comparison

In the type 2 diabetes population, retatrutide 8-12 mg produced 23-26% reductions in total body fat mass, substantially greater than the 2.6% reduction with dulaglutide 1.5 mg [4]. The magnitude of fat mass reduction with retatrutide appears proportional to its greater overall weight loss effect.

Clinical Implications

The available evidence suggests that:

Retatrutide produces substantial, dose-dependent reductions in body fat mass that are statistically and clinically significant compared to placebo and GLP-1 receptor agonists [4]

The proportion of lean mass to fat mass loss appears preserved despite greater total weight loss, suggesting the quality of weight loss is maintained [4]

No bone mineral density data are currently available from published DXA substudies, representing an important knowledge gap given the magnitude of weight loss achieved

Direct DXA comparisons with semaglutide and tirzepatide are not yet published, limiting definitive conclusions about relative body composition effects

The authors concluded that these findings "could provide reassurance that a greater proportion of lean mass is not lost with retatrutide despite the overall increased weight loss" [4], though they acknowledged the need for ongoing monitoring of body composition changes with this potent weight loss agent.

References

[4] Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. 2025. https://doi.org/10.1016/s2213-8587(25" rel="noopener" target="_blank">https://doi.org/10.1016/s2213-8587(25)00092-0

Bone & lean mass sources

[1] Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. (2023) — https://doi.org/10.1056/nejmoa2301972

[2] Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. (2023) — https://doi.org/10.1016/s0140-6736(23)01053-x

[3] Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. (2024) — https://doi.org/10.1038/s41591-024-03018-2

[4] Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. (2025) — https://doi.org/10.1016/s2213-8587(25)00092-0

[5] Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. (2024) — https://doi.org/10.1038/s41421-024-00700-0

[6] Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP. (2025) — https://doi.org/10.1002/advs.202407494

[7] Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. (2025) — https://doi.org/10.1007/s12020-024-03998-8

[8] Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. (2024) — https://doi.org/10.1016/j.metop.2024.100321

[9] Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. (2025) — https://doi.org/10.1111/dom.16661

[10] Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. (2026) — https://doi.org/10.1111/dom.70209

[11] Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence. (2024) — https://doi.org/10.1002/hsr2.1864

[12] Retatrutide-A Game Changer in Obesity Pharmacotherapy. (2025) — https://doi.org/10.3390/biom15060796